High-affinity interactions of ligands at recombinant Guinea pig 5HT7 receptors

The serotonin 5HT7 receptor has been implicated in numerous physiological and pathological processes from circadian rhythms [1] to depression and schizophrenia. Clonal cell lines heterologously expressing recombinant receptors offer good models for understanding drug-receptor interactions and development of quantitative structure-activity relationships (QSAR). Comparative Molecular Field Analysis (CoMFA) is an important modern QSAR procedure that relates the steric and electrostatic fields of a set of aligned compounds to affinity. Here, we utilized CoMFA to predict affinity for a number of high-affinity ligands at the recombinant guinea pig 5HT7 receptor. Using R-lisuride as the template, a final CoMFA model was derived using procedures similar to those of our recent papers [2, 3, 4] The final cross-validated model accounted for >85% of the variance in the compound affinity data, while the final non-cross validated model accounted for >99% of the variance. Model evaluation was done using cross-validation methods with groups of 5 ligands. Twenty cross-validation runs yielded an average predictive r2(q2) of 0.779 ± 0.015 (range: 0.669–0.867). Furthermore, 3D-chemical database search queries derived from the model yielded hit lists of promising agents with high structural similarity to the template. Together, these results suggest a possible basis for high-affinity drug action at 5HT7 receptors.

[1]  M. Erlander,et al.  A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms , 1993, Neuron.

[2]  Ralph E. Christoffersen,et al.  Computer-assisted drug design , 1979 .

[3]  P J Lovell,et al.  A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970). , 2000, Journal of medicinal chemistry.

[4]  R. Kohen,et al.  Gs Protein‐Coupled Serotonin Receptors: Receptor Isoforms and Functional Differences , 1998, Annals of the New York Academy of Sciences.

[5]  A. Tsou,et al.  Cloning and Expression of a 5‐Hydroxytryptamine7 Receptor Positively Coupled to Adenylyl Cyclase , 1994, Journal of neurochemistry.

[6]  R E Wilcox,et al.  CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors. , 1998, Journal of medicinal chemistry.

[7]  G. Edwards Textbook of psychopharmacology , 1975, Nature.

[8]  K. Neve,et al.  Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors. , 1996, Journal of medicinal chemistry.

[9]  R D Cramer,et al.  Application of quantitative structure-activity relationships in the development of the antiallergic pyranenamines. , 1979, Journal of medicinal chemistry.

[10]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[11]  D. Sibley,et al.  Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. , 1993, The Journal of biological chemistry.

[12]  Y. Martin Computer-assisted rational drug design. , 1991, Methods in enzymology.

[13]  G R Marshall,et al.  3D-QSAR: a current perspective. , 1995, Trends in pharmacological sciences.

[14]  L. Jellett,et al.  Log-normal distribution of equiefective doses of norepinephrine and acetylcholine in several tissues. , 1972, The Journal of pharmacology and experimental therapeutics.

[15]  G. Martin,et al.  The 5-HT7 receptor: orphan found. , 1997, Trends in pharmacological sciences.

[16]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[17]  M. Varasi,et al.  Ergoline derivatives: receptor affinity and selectivity. , 1999, Farmaco.

[18]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[19]  A. IJzerman,et al.  A model of the serotonin 5-HT1A receptor: agonist and antagonist binding sites. , 1994, Drug design and discovery.

[20]  J. Zgombick,et al.  LY215840, a high-affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery. , 1996, The Journal of pharmacology and experimental therapeutics.

[21]  K. Neve,et al.  Dopamine Receptors , 2008 .

[22]  K. Neve,et al.  CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors. , 2000, Journal of medicinal chemistry.

[23]  C E Berkoff,et al.  Substructural analysis. A novel approach to the problem of drug design. , 1974, Journal of medicinal chemistry.

[24]  J. Schuurkes,et al.  Evidence for 5‐HT7 receptors mediating relaxation of human colonic circular smooth muscle , 1999, British journal of pharmacology.

[25]  R. Eglen,et al.  Cloning, expression and pharmacology of a truncated splice variant of the human 5‐HT7 receptor (h5‐HT7(b)) , 1997 .

[26]  A. Eison,et al.  Effects of Antidepressants on 5-HT7 Receptor Regulation in the Rat Hypothalamus , 1999, Neuropsychopharmacology.

[27]  Hugo Kubinyi,et al.  3D QSAR in drug design : theory, methods and applications , 2000 .

[28]  Atul Agarwal,et al.  3‐D QSAR for intrinsic activity of 5‐HT1A receptor ligands by the method of comparative molecular field analysis , 1993, J. Comput. Chem..